EA201200096A1 - Фармацевтическая композиция ингибитора протеазы вируса гепатита c - Google Patents

Фармацевтическая композиция ингибитора протеазы вируса гепатита c

Info

Publication number
EA201200096A1
EA201200096A1 EA201200096A EA201200096A EA201200096A1 EA 201200096 A1 EA201200096 A1 EA 201200096A1 EA 201200096 A EA201200096 A EA 201200096A EA 201200096 A EA201200096 A EA 201200096A EA 201200096 A1 EA201200096 A1 EA 201200096A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
inhibitor
hypatitis
virus protease
protease inhibitor
Prior art date
Application number
EA201200096A
Other languages
English (en)
Other versions
EA023433B1 (ru
Inventor
Фэнцзин Чэнь
Роберт Дж. Швабе
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201200096A1 publication Critical patent/EA201200096A1/ru
Publication of EA023433B1 publication Critical patent/EA023433B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

В заявке описана фармацевтическая композиция ингибитора протеазы вируса гепатита С, которую можно использовать для орального введения в виде капсулы, заполненной жидкостью или полутвердым веществом, способы применения этой композиции для ингибирования репликации вируса гепатита С (HCV) и лечения инфекции, вызываемой HCV. Жидкая или полутвердая фармацевтическая композиция, предлагаемая в настоящем изобретении, содержит соединение формулы I или его фармацевтически приемлемую соль в сочетании с одним или несколькими фармацевтически приемлемыми липидами и гидрофильными поверхностно-активными веществами.
EA201200096A 2009-07-07 2010-07-01 Фармацевтическая композиция ингибитора протеазы вируса гепатита c EA023433B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22350709P 2009-07-07 2009-07-07
PCT/US2010/040734 WO2011005646A2 (en) 2009-07-07 2010-07-01 Pharmaceutical composition for a hepatitis c viral protease inhibitor

Publications (2)

Publication Number Publication Date
EA201200096A1 true EA201200096A1 (ru) 2012-08-30
EA023433B1 EA023433B1 (ru) 2016-06-30

Family

ID=43245003

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200096A EA023433B1 (ru) 2009-07-07 2010-07-01 Фармацевтическая композиция ингибитора протеазы вируса гепатита c

Country Status (35)

Country Link
US (1) US9034831B2 (ru)
EP (1) EP2451438B8 (ru)
JP (1) JP5607736B2 (ru)
KR (1) KR101685941B1 (ru)
CN (1) CN102470103B (ru)
AP (1) AP2011005979A0 (ru)
AR (1) AR077393A1 (ru)
AU (1) AU2010270783B2 (ru)
BR (1) BR112012000287B8 (ru)
CA (1) CA2767692C (ru)
CL (1) CL2012000054A1 (ru)
CO (1) CO6480980A2 (ru)
DK (1) DK2451438T3 (ru)
EA (1) EA023433B1 (ru)
EC (1) ECSP12011624A (ru)
ES (1) ES2464367T3 (ru)
GE (1) GEP20146016B (ru)
HR (1) HRP20140445T1 (ru)
IL (1) IL216098A (ru)
MA (1) MA33491B1 (ru)
ME (1) ME01718B (ru)
MX (1) MX2011013824A (ru)
MY (1) MY154683A (ru)
NZ (1) NZ596928A (ru)
PE (1) PE20120322A1 (ru)
PL (1) PL2451438T3 (ru)
PT (1) PT2451438E (ru)
RS (1) RS53209B (ru)
SG (1) SG177569A1 (ru)
SI (1) SI2451438T1 (ru)
TN (1) TN2012000009A1 (ru)
TW (1) TWI490216B (ru)
UA (1) UA104195C2 (ru)
UY (1) UY32760A (ru)
WO (1) WO2011005646A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926642B2 (en) 2020-04-05 2024-03-12 Pfizer Inc. Compounds and methods for the treatment of COVID-19

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103496C2 (ru) * 2008-09-17 2013-10-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Комбинация ингибитора протеазы ns3 hcv с интерфероном и рибавирином
PT2451438E (pt) 2009-07-07 2014-03-26 Boehringer Ingelheim Int Composição farmacêutica para um inibidor de protease viral da hepatite c
EP2493470A1 (en) 2009-10-30 2012-09-05 Boehringer Ingelheim International GmbH Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
JP2013540112A (ja) 2010-09-30 2013-10-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ感染を治療するための併用療法
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2572328B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para su uso en el tratamiento del vhc
DE202012012954U1 (de) 2011-10-21 2014-08-12 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
SG11201404042VA (en) 2012-01-12 2014-08-28 Boehringer Ingelheim Int Stabilized pharmaceutical formulations of a potent hcv inhibitor
WO2013137869A1 (en) 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147749A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient subgenotype populations
WO2013147750A1 (en) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
EA032322B1 (ru) * 2013-03-15 2019-05-31 Бёрингер Ингельхайм Интернациональ Гмбх Твердая пероральная дозированная композиция ингибитора hcv в аморфном состоянии
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2907460A1 (de) 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
IL102236A0 (en) 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
US5329976A (en) 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
DE69435104D1 (de) 1993-09-28 2008-07-31 Scherer Gmbh R P Herstellung von Weichgelatinekapseln
JPH11505257A (ja) 1995-05-19 1999-05-18 アボツト・ラボラトリーズ 親油性薬物の自己乳化性製剤
US5993858A (en) 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
DE69808463T2 (de) 1997-07-29 2003-06-26 Upjohn Co Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
DE69804624T2 (de) 1997-07-29 2002-09-19 Upjohn Co Selbstemulgierende formulierung enthaltend lipophile verbindungen
ES2219895T3 (es) * 1997-07-29 2004-12-01 PHARMACIA & UPJOHN COMPANY Formulacion autoemulsionante para compuestos lipofilos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2466851C (en) 2001-11-26 2012-09-11 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US20040033959A1 (en) * 2002-07-19 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical compositions for hepatitis C viral protease inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
UY28240A1 (es) 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
NZ543250A (en) 2003-04-02 2008-12-24 Boehringer Ingelheim Int Pharmaceutical compositions for hepatitis C viral protease inhibitors
PL1654261T3 (pl) * 2003-05-21 2008-04-30 Boehringer Ingelheim Int Związki hamujące aktywność wirusa zapalenia wątroby typu C
PE20050431A1 (es) 2003-09-22 2005-07-19 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c
BRPI0508867A (pt) 2004-03-15 2007-09-04 Boehringer Ingelheim Int processo para a preparação de compostos macrocìclicos
AP2006003763A0 (en) 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
US7514557B2 (en) 2004-05-25 2009-04-07 Boehringer Ingelheim International Gmbh Process for preparing acyclic HCV protease inhibitors
WO2006130552A2 (en) 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
BRPI0908021A2 (pt) 2008-02-04 2015-07-21 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
DK2331538T3 (da) 2008-09-16 2014-06-02 Boehringer Ingelheim Int Krystallinske former af en 2-thiazolyl-4-quinolinyl-oxy-derivat, en potent HCV-inhibitor
MY155402A (en) 2008-11-21 2015-10-15 Boehringer Ingelheim Int Pharmaceutical composition of a potent hcv inhibitor for oral administration
PT2451438E (pt) 2009-07-07 2014-03-26 Boehringer Ingelheim Int Composição farmacêutica para um inibidor de protease viral da hepatite c

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11926642B2 (en) 2020-04-05 2024-03-12 Pfizer Inc. Compounds and methods for the treatment of COVID-19

Also Published As

Publication number Publication date
CA2767692C (en) 2017-03-07
ECSP12011624A (es) 2012-02-29
HRP20140445T1 (hr) 2014-06-20
ME01718B (me) 2014-09-20
EP2451438B8 (en) 2014-04-09
US20110160149A1 (en) 2011-06-30
CN102470103B (zh) 2016-09-07
WO2011005646A3 (en) 2011-12-22
UA104195C2 (ru) 2014-01-10
GEP20146016B (en) 2014-01-27
CL2012000054A1 (es) 2012-10-12
UY32760A (es) 2011-02-28
CA2767692A1 (en) 2011-01-13
MA33491B1 (fr) 2012-08-01
KR20120059481A (ko) 2012-06-08
AR077393A1 (es) 2011-08-24
IL216098A0 (en) 2012-01-31
BR112012000287A2 (pt) 2016-02-23
NZ596928A (en) 2013-05-31
JP5607736B2 (ja) 2014-10-15
BR112012000287B8 (pt) 2021-05-25
AU2010270783B2 (en) 2013-06-27
US9034831B2 (en) 2015-05-19
RS53209B (en) 2014-06-30
CN102470103A (zh) 2012-05-23
SI2451438T1 (sl) 2014-04-30
JP2012532192A (ja) 2012-12-13
EA023433B1 (ru) 2016-06-30
KR101685941B1 (ko) 2016-12-13
WO2011005646A2 (en) 2011-01-13
EP2451438B1 (en) 2014-02-26
PE20120322A1 (es) 2012-04-14
PL2451438T3 (pl) 2014-07-31
AP2011005979A0 (en) 2011-12-31
MY154683A (en) 2015-07-15
IL216098A (en) 2016-02-29
TN2012000009A1 (en) 2013-09-19
DK2451438T3 (da) 2014-03-10
TW201114766A (en) 2011-05-01
SG177569A1 (en) 2012-03-29
CO6480980A2 (es) 2012-07-16
BR112012000287B1 (pt) 2020-12-08
TWI490216B (zh) 2015-07-01
EP2451438A2 (en) 2012-05-16
AU2010270783A1 (en) 2011-12-15
ES2464367T3 (es) 2014-06-02
MX2011013824A (es) 2012-01-30
PT2451438E (pt) 2014-03-26

Similar Documents

Publication Publication Date Title
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
UY37998A (es) Agentes antivirales contra la hepatitis b
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201201031A1 (ru) Ингибиторы вируса гепатита с
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
BR112012018670A2 (pt) combinação, uso de um composto, composição farmacêutica, e, pacote de paciente
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
DK2250163T3 (da) Hepatitis C-virusinhibitorer
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
CL2012001449A1 (es) Uso de combinaciones del compuesto n-[(ciclopentiloxi)carbonil]-3-metil-l-valiol-(4r)-4-({8-bromo-2-[2-(isobutirilamino)-1,3-tiazol-4-il]-7-metoxi-4-quinolinil}oxi)-n-[(1r,2s)-1-carboxi-2-vinilciclopropil]-l-prolinamida; y envase que comprende las formas de dosificacion.
RU2014122154A (ru) Композиции, пригодные для лечения вирусных заболеваний
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
BR112013028679A2 (pt) inibidores do vírus da hepatite c
EA201170512A1 (ru) Композиция для перорального введения
EA201490573A1 (ru) Соединение бензотиазолона
RU2015114566A (ru) Способы лечения гепатита с
EA201300422A1 (ru) Твердофазные формы активного ингибитора hcv
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
CY1115027T1 (el) Φαρμακευτικη συνθεση για αναστολεα ιικης πρωτεασης ηπατιτιδας c
EA201200799A1 (ru) Гепатопротекторное средство
EA202091903A1 (ru) Кристаллическая форма битегравир-натрия

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU